Convertible Notice
$58,400,000
11/09/2022
Rockville, Maryland
Healthcare & Prescription drugs
B2B/B2C
20/20 GeneSystems, with a valuation of $58.4 million, is elevating funds on StartEngine. It’s a diagnostics firm with a profitable observe document in most cancers detection with its AI-powered multi-cancer blood check, OneTest. The corporate has additionally launched CoronaCheck, its FDA-authorized antibody lab check for COVID-19 antibodies. The enterprise reported revenues of $9 million in 2021, a 300% improve over 2020 revenues. Jonathan Cohen based 20/20 GeneSystems in 2000. The present crowdfunding marketing campaign has a minimal goal of $9,995.40 and a most goal of $4,999,995. The marketing campaign proceeds will likely be used to broaden the portfolio of exams and develop revenues.
Abstract Revenue and Loss Assertion
|
Income |
$9,622,332 |
$2,330,528 |
|
COGS |
$4,927,374 |
$1,453,354 |
|
Tax |
$0 |
$0 |
|
|
||
|
|
||
|
Internet Earnings |
$2,071,777 |
$-2,021,826 |
Abstract Steadiness Sheet
|
Money |
$3,354,469 |
$3,468,192 |
|
Accounts Receivable |
$4,215,465 |
$205,071 |
|
Complete Belongings |
$10,272,281 |
$4,677,734 |
|
Brief-Time period Debt |
$0 |
$103,860 |
|
Lengthy-Time period Debt |
$0 |
$40,247 |
|
Complete Liabilities |
$0 |
$144,107 |
Financials as of: 08/16/2022
Elevate Historical past
| 20/20 GeneSystems | 11/15/2022 | StartEngine | $58,400,000 | $158,061 | Convertible Notice |
Lively |
RegCF |
| 20/20 GeneSystems | 06/27/2021 | StartEngine | $38,500,000 | $2,903,017 | Fairness – Most well-liked |
Funded |
RegA+ |
| 20/20 GeneSystems | 11/01/2020 | SeedInvest | $38,500,000 | $3,792,229 | Fairness – Most well-liked |
Funded |
RegA+ |
| 20/20 GeneSystems | 12/14/2017 | Microventures | $23,000,000 | $1,064,807 | Fairness – Most well-liked |
Funded |
RegCF |
